ASK-lAb

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Exploring the “N-Terminal Anchor” Binding Interface of the T3SS Chaperone–Translocator Complexes from P. aeruginosa

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in MS

COVID-19 vaccine response in people with multiple sclerosis

Immunogenicity of biologics used in the treatment of moderate to severe psoriasis

Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review

Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis